Search research articles
Contact Us
Filters
Showing results (151-160 of 198) with videos related to
Page
of 20
Sort By:
Cancer Genetics
|
June 19, 2026
Comprehensive genome-wide association study into multiple recurrence and progression risk in non-muscle invasive bladder cancer
Jasper P Hof, Tessel E Galesloot, Katja K H Aben, et al.
The Lancet. Oncology
|
April 14, 2022
Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial
Syed A Hussain, Jason F Lester, Richard Jackson, et al.
The Journal of Clinical Investigation
|
March 31, 2026
Proliferation associates with greater sensitivity to androgen receptor pathway inhibition for metastatic prostate cancer
Larissa Mendes, Peter F Dutey-Magni, Emily Grist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 24, 2006
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor
Jennifer C C Hu, Robert S Coffin, Ceri J Davis, et al.
BJU International
|
May 12, 2019
Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification
Douglas G Ward, Naheema S Gordon, Rebecca H Boucher, et al.
Plos One
|
June 2, 2022
Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data
Caroline S Clarke, Rachael M Hunter, Andrea Gabrio, et al.
Clinical Epigenetics
|
February 7, 2017
UroMark-a urinary biomarker assay for the detection of bladder cancer
Andrew Feber, Pawan Dhami, Liqin Dong, et al.
BJU International
|
November 14, 2013
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma
Gregory R Pond, Neeraj Agarwal, Joaquim Bellmunt, et al.
Science (New York, N.Y.)
|
September 21, 2023
Recovery of walking after paralysis by regenerating characterized neurons to their natural target region
Jordan W Squair, Marco Milano, Alexandra de Coucy, et al.
JCO Precision Oncology
|
January 20, 2022
Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial
Clare Gilson, Fiona Ingleby, Duncan C Gilbert, et al.
Page
of 20
Search research articles
Search
Showing results (151-160 of 198) with videos related to
Sort By:
Page
of 20
Cancer Genetics
|
June 19, 2026
Comprehensive genome-wide association study into multiple recurrence and progression risk in non-muscle invasive bladder cancer
Jasper P Hof, Tessel E Galesloot, Katja K H Aben, et al.
The Lancet. Oncology
|
April 14, 2022
Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial
Syed A Hussain, Jason F Lester, Richard Jackson, et al.
The Journal of Clinical Investigation
|
March 31, 2026
Proliferation associates with greater sensitivity to androgen receptor pathway inhibition for metastatic prostate cancer
Larissa Mendes, Peter F Dutey-Magni, Emily Grist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 24, 2006
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor
Jennifer C C Hu, Robert S Coffin, Ceri J Davis, et al.
BJU International
|
May 12, 2019
Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification
Douglas G Ward, Naheema S Gordon, Rebecca H Boucher, et al.
Plos One
|
June 2, 2022
Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data
Caroline S Clarke, Rachael M Hunter, Andrea Gabrio, et al.
Clinical Epigenetics
|
February 7, 2017
UroMark-a urinary biomarker assay for the detection of bladder cancer
Andrew Feber, Pawan Dhami, Liqin Dong, et al.
BJU International
|
November 14, 2013
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma
Gregory R Pond, Neeraj Agarwal, Joaquim Bellmunt, et al.
Science (New York, N.Y.)
|
September 21, 2023
Recovery of walking after paralysis by regenerating characterized neurons to their natural target region
Jordan W Squair, Marco Milano, Alexandra de Coucy, et al.
JCO Precision Oncology
|
January 20, 2022
Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial
Clare Gilson, Fiona Ingleby, Duncan C Gilbert, et al.
Page
of 20